Phase I Clinical Trial with the AMC-Bioartificial Liver

Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF patients waiting for (OLT) was started in Italy. We present the safety outcome of the first 7 patients aged 21–56 years with coma grade III or IV. The total AMC-BAL treatment time ranged from 8 to 35 hours. Three patients received 2 treatments with two different BAL's within three days. Six of the 7 patients were successfully bridged to OLT. One patient showed improved liver function after two treatments and did not need OLT. No severe adverse events of the BAL treatment were noted. Conclusion Treatment of ALF patients with the AMC-BAL is a safe and feasible technique to bridge the waiting time for an adequate liver-graft.

[1]  R Williams,et al.  Early indicators of prognosis in fulminant hepatic failure. , 1989, Gastroenterology.

[2]  L. Flendrig,et al.  Functional activity of isolated pig hepatocytes attached to different extracellular matrix substrates. Implication for application of pig hepatocytes in a bioartificial liver. , 1995, Journal of hepatology.

[3]  R. Chamuleau,et al.  Recent Developments on Human Cell Lines for the Bioartificial Liver , 2002, The International journal of artificial organs.

[4]  L. Podestá,et al.  A Bioartificial Liver to Treat Severe Acute Liver Failure , 1994, Annals of surgery.

[5]  L. Flendrig,et al.  Immunological Consequences of the use of Xenogeneic Hepatocytes in a Bioartificial Liver for Acute Liver Failure , 1997, The International journal of artificial organs.

[6]  N. Sussman,et al.  Extracorporeal liver support. Application to fulminant hepatic failure. , 1994, Journal of clinical gastroenterology.

[7]  N. Sussman,et al.  Improved liver function following treatment with an extracorporeal liver assist device. , 2008, Artificial organs.

[8]  R. Weiss,et al.  Host range and interference studies of three classes of pig endogenous retrovirus. , 1999, Journal of virology.

[9]  W. Heneine,et al.  Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. , 1999, Science.

[10]  M. Matsushita,et al.  Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum. , 1993, ASAIO journal.

[11]  W. Wall,et al.  Liver transplantation for fulminant hepatic failure: North American experience. , 1995, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  Philippe Ichai,et al.  Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. , 2002, Transplantation.

[13]  L. Flendrig,et al.  Possible Immunological Problems of Bioartificial Liver Support , 1997, The International journal of artificial organs.

[14]  D. Relman,et al.  Identification of the uncultured bacillus of Whipple's disease. , 1992, The New England journal of medicine.

[15]  E. Keeffe,et al.  Liver transplantation: current status and novel approaches to liver replacement. , 2001, Gastroenterology.

[16]  O. Karlsen,et al.  UvA-DARE ( Digital Academic Repository ) In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates , 2001 .

[17]  A. Demetriou,et al.  Clinical Experience with a Porcine Hepatocyte-Based Liver Support System , 1996, The International journal of artificial organs.

[18]  A. Demetriou,et al.  Clinical Use of a Bioartificial Liver in the Treatment of Acetaminophen-Induced Fulminant Hepatic Failure , 1999, The American surgeon.

[19]  B. Torbett,et al.  Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice , 2000, Nature.

[20]  M. Slavik,et al.  Phase I clinical trials. , 1977, National Cancer Institute monograph.

[21]  W. Arnaout,et al.  Use of a novel bioartificial liver in a patient with acute liver insufficiency. , 1993, Surgery.

[22]  Experimental evaluation of a hybrid liver support system. , 1997, Transplantation proceedings.

[23]  C. Cochrane,et al.  Pathogenesis of serum sickness. , 1958, A.M.A. archives of pathology.

[24]  J. Lake,et al.  Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure , 1992, Hepatology.

[25]  L. Flendrig,et al.  Evaluation of a novel bioartificial liver in rats with complete liver ischemia: treatment efficacy and species-specific alpha-GST detection to monitor hepatocyte viability. , 1999, Journal of hepatology.

[26]  A. Demetriou,et al.  Treatment of Severe Liver Failure with a Bioartificial Liver a , 1997, Annals of the New York Academy of Sciences.

[27]  H. Conn,et al.  The hepatic coma syndromes and lactulose , 1980 .

[28]  Thomas M van Gulik,et al.  ASSESSMENT OF THE AMC-BIOARTIFICIAL LIVER IN THE ANHEPATIC PIG1 , 2002, Transplantation.

[29]  J. Stoves,et al.  The bradykinin response and early hypotension at the introduction of continuous renal replacement therapy in the intensive care unit. , 2001, Artificial organs.

[30]  Alistair Lee,et al.  Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure , 1999, The Lancet.

[31]  P. Neuhaus,et al.  Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study , 2000, The Lancet.

[32]  N. Sussman,et al.  The Hepatix extracorporeal liver assist device: initial clinical experience. , 1994, Artificial organs.

[33]  D H Persing,et al.  Transfer of porcine endogenous retrovirus across hollow fiber membranes: significance to a bioartificial liver. , 1999, Transplantation.

[34]  G. Mazariegos,et al.  Safety Observations in Phase I Clinical Evaluation of the Excorp Medical Bioartificial Liver Support System after the First Four Patients , 2001, ASAIO journal.

[35]  R. Busuttil,et al.  Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment: an ex vivo model of pig to human xenotransplantation. , 1999, Transplantation.

[36]  J. Gerlach.  Long-term liver cell cultures in bioreactors and possible application for liver support , 1997, Cell Biology and Toxicology.

[37]  X. M. Fernández-Suárez,et al.  Monitoring xenotransplant recipients for infection by PERV. , 2001, Clinical biochemistry.

[38]  B. Yvonnet,et al.  Multivariate analysis of prognostic factors in fulminant hepatitis B , 1986, Hepatology.

[39]  C. Mullon,et al.  Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. , 1999, Artificial organs.

[40]  A. Demetriou,et al.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. , 1997, Annals of surgery.

[41]  R Williams,et al.  Pilot‐controlled trial of the extracorporeal liver assist device in acute liver failure , 1996, Hepatology.

[42]  K Sugimachi,et al.  Modulation of immunologic reactions between cultured porcine hepatocytes and human sera. , 1999, ASAIO journal.

[43]  M V Peshwa,et al.  Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. , 1994, Annals of surgery.

[44]  A F Angulo,et al.  Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification , 1992, Applied and environmental microbiology.

[45]  L. Flendrig,et al.  Significantly Improved Survival Time in Pigs with Complete Liver Ischemia Treated with a Novel Bioartificial Liver , 1999, The International journal of artificial organs.

[46]  J. Bernuau,et al.  Fulminant and Subfulminant Liver Failure: Definitions and Causes , 1986, Seminars in liver disease.